2018 - 2017 - 2016 - 2015 - 2014 - 2013 - 2012 - 2011 - 2010 - 2009

Cannabis Science, Inc. (CBIS) Announces Submission of Cannabinoid-Based Patent Application N2010968 Titled 'Composition for the Treatment of Neurobehavioral Disorders'

Cannabis Science, Inc. (CBIS) Announces Submission of Cannabinoid-Based Patent Application N2010968 Titled 'Composition for the Treatment of Neurobehavioral Disorders'

COLORADO SPRINGS, Colo., Nov. 15, 2013 /PRNewswire/ -- (NASDAQ OTC: CBIS) Cannabis Science, Inc., a U.S. Company specializing in cannabis formulation-based drug development, proudly announces the submission of a patent application N2010968 in Europe entitled "Composition for the Treatment of Neurobehavioral Disorders." The patent's inventors, Mario Lap, Director and President of European Operations, Dr. Dorothy Bray, Director and CEO, and Alfredo Dupetit, Vice President for European Research and Development of the Company, filed the patent application on behalf of Cannabis Science, which owns all of the rights and interests in the patent.

The subject of the patent is development of cannabinoid-based formulations to treat a variety of neurobehavioral disorders, such as attention deficit hyperactivity disorder (ADHD), anxiety, and sleep disorders. The World Health Organization (WHO) reports that about 450 million people worldwide suffer from some form of mental or neurobehavioral disorder or brain condition, and that one in four people meet criteria for such a condition or disorder at some point in their life. Many of these conditions occur in children and adolescents. Mean worldwide prevalence of ADHD is between 5.29% and 7.1% and is often present alongside co-morbidities such as oppositional defiant disorder (ODD) and anxiety disorder. Source: http://www.adhd-institute.com/burden-of-adhd/epidemiology/#sthash.GJFBfvZL.dpuf

Targeted neurobehavioral conditions also include sleeping and sleep-related disorders that have global impact. Recently published Australian research has found sleep disorders cost the Australian economy more than $5 billion a year in health care and indirect costs. In the USA the annual direct cost of sleep-related problems is $16 billion, with an additional $50-$100 billion in indirect costs. Source: http://umm.edu/programs/sleep/health/sleep-disorders#ixzz2kfVv0ZRH

"Following this patent announcement, we expect to have additional filings in the near future as our research continues. Being personally and professionally close to people with ADHD, anxiety, and sleeping disorders, I am excited about the Board's decision to focus on treating these ailments in the Company's overall strategy," stated Chad Johnson, COO and General Counsel, Cannabis Science, Inc.

Cannabis Science's IP strategy includes developing, owning, and licensing patents for the Company's proprietary drug development operations and collaborations with other industry actors to most effectively help patients.

"The information database we have is impressive. Research and development are critical for understanding the novel formulations and use of compounds in our pipeline as well as to use that information to create innovative and effective products. We believe the Company has the means to achieve this goal through a variety of formulations and we intend to vigorously protect our intellectual property," stated Dr. Dorothy Bray, Director and CEO, Cannabis Science, Inc.

About Cannabis Science, Inc.
Cannabis Science, Inc. takes advantage of its unique understanding of metabolic processes to provide novel treatment approaches to a number of illnesses for which current treatments and understanding remain unsatisfactory. Cannabinoids have an extensive history dating back thousands of years, and currently there are a growing number of peer-reviewed scientific publications that document the underlying biochemical pathways that cannabinoids modulate. The Company works with leading experts in drug development, medicinal characterization, and clinical research to develop, produce, and commercialize novel therapeutic approaches for the treatment for illnesses caused by infections as well as for age-related illness. Our initial focus is on skin cancers and HIV related cancers such as Kaposi's Sarcoma.

Forward Looking Statements
This Press Release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Act of 1934. A statement containing works such as "anticipate," "seek," intend," "believe," "estimate," "expect," "project," "plan," or similar phrases may be deemed "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Some or all of the events or results anticipated by these forward-looking statements may not occur. Factors that could cause or contribute to such differences include the future U.S. and global economies, the impact of competition, and the Company's reliance on existing regulations regarding the use and development of cannabis-based drugs. Cannabis Science, Inc. does not undertake any duty nor does it intend to update the results of these forward-looking statements.